Psychedelic companies hoping to capitalize on a surging interest in psilocybin treatments have been limited to one source for research grade psilocybin. Until now.
The big question is how does this action resolve itself?
Real Money tapped an industry expert to discuss the outlook for buying and selling of cannabis companies.
It requires some increased emphasis on defense just in case it develops into something more significant.
Traders interested in the retailer of hydroponic equipment should wait for some sideways trading action before probing the long side.
If the Democrats sweep, you have perhaps the best single stock in the market.
Despite the bumps and bearish arguments, we still see some good stock picking.
I'm growing increasingly cautious but I'm still finding some stock picks that are working.
While breadth is very good Wednesday, it isn't flowing into the speculative names.
Value customers drive move away luxury pot products.